Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.
- BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.
- “We are thrilled to welcome Gene as our new CFO,” commented Gain CEO Matthias Alder.
- Prior to joining Gain, Gene was CFO at privately held Imcyse SA between 2021 and 2023.
- “I am excited to join Gain Therapeutics during this important stage of corporate growth and scientific progression.